Cancer Research and Treatment

Original Articles

LncRNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2 Stability: Wenwei Ying, Dingliang Li, Ninghan Feng, Wei Wei; Received April 30, 2025 Accepted September 17, 2025 Published online September 18, 2025; DOI: https://doi.org/10.4143/crt.2025.468 [Accepted]

Abstract PDF: Purpose
Long noncoding RNAs (lncRNAs) are increasingly being recognized to play important roles in cancer pathogenesis. However, the functional mechanisms of most lncRNAs remain poorly understood.
Materials and Methods
RNA sequencing was performed to identify differentially expressed lncRNAs between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). In vitro and in vivo assays were conducted to investigate the functional role of lncRNA deoxyguanosine kinase 1 antisense RNA 1 (DGUOK-AS1). Meanwhile, RNA pull-down, RNA immunoprecipitation, co-immunoprecipitation, Western blot, and reverse transcription quantitative polymerase chain reaction assays were performed to explore the potential regulatory mechanisms of DGUOK-AS1 on its target genes.
Results
Our analysis revealed a significant upregulation of lncRNA DGUOK-AS1 in MIBC compared with NMIBC. Functionally, DGUOK-AS1 was found to enhance the proliferation and invasion of bladder cancer (BC) cells by interacting with elongation factor Tu GTP binding domain containing 2 (EFTUD2), a 116-kDa U5 small nuclear ribonucleoprotein component. Mechanistically, DGUOK-AS1 directly binds to EFTUD2 and the deubiquitinating protein valosin-containing protein-interacting protein 1, thereby shielding EFTUD2 from ubiquitination and subsequent degradation. Furthermore, EFTUD2 orchestrates the exclusion of cassette exon 11 from macrophage-stimulating 1 receptor, leading to the production of the RON∆165 isoform. This isoform activates the Akt/PKB signaling pathway, which is crucial for cancer progression.
Conclusion
DGUOK-AS1 drives BC progression via the EFTUD2/MST1R/Akt axis, offering a promising therapeutic target for BC treatment.

658 View
33 Download

Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin for Muscle-Invasive Bladder Cancer Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial: Zhou Tong, Guanghou Fu, Feng Zhou, Xiaoyan Liu, Xing Xue, Hangyu Zhang, Yimin Wang, Xudong Zhu, Yang Gao, Lulu Liu, Xuanwen Bao, Yi Zheng, Weijia Fang, Peng Zhao, Baiye Jin; Received February 24, 2025 Accepted April 22, 2025 Published online April 28, 2025; DOI: https://doi.org/10.4143/crt.2025.214 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to evaluate the safety and efficacy of gemcitabine and cisplatin (GP) regimen in combination with immune checkpoint inhibitor sintilimab as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) patients and the feasibility of the following selective bladder sparing surgery.
Materials and Methods
Patients with histopathological confirmed urothelial carcinoma without distant metastases (T2-4a, N ≤ 1, M0, American Joint Committee of Cancer 8th) and with adequate organ function will be enrolled. The therapeutic regimen was sintilimab 200 mg once on day 8, gemcitabine 1,000 mg/m² and cisplatin 35 mg/m² once on days 1 and 8, every 21 days for four cycles. The primary endpoint was pathologic complete response (pCR, pT0N0) rate. The secondary end points were ypT < 2 rate, R0 resection rate, event-free survival, and safety.
Results
From May 4, 2020, to May 20, 2023, 55 patients were enrolled. Forty-six patients were evaluated for efficacy. Among the 42 patients who underwent surgery, 16 patients (38.0%) achieved pCR. Thirty-three patients (78.6%) achieved pT < 2. With a median follow-up of 15.7 months, the 1-year event-free survival was 91.3%. Notwithstanding the poor pathological baseline characteristic of a high T3-T4a proportion (39.1%), a promising bladder preservation (including 22 patients transurethral resection of bladder tumor, 5 patients partial cystectomy, and 4 surveillances) rate was achieved (67.4%). The most common grade ≥ 3 treatment-related adverse events was neutropenia (n=15, 27.3%), which was related to chemotherapy. There were no grade 3 immune-related adverse events.
Conclusion
Neoadjuvant GP plus sintilimab is a promising regimen for MIBC patients, with relatively high pT < 2 rate and triggering the emerging roles for the multi-disciplinary team decision-making for bladder sparing surgery.

1,164 View
104 Download

Genitourinary cancer

Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies: Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park; Cancer Res Treat. 2024;56(3):893-897. Published online February 15, 2024; DOI: https://doi.org/10.4143/crt.2024.015

Abstract PDF PubReader ePub

Purpose
Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT.
Materials and Methods
The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT.
Results
Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976).
Conclusion
The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.

Citations

Citations to this article as recorded by

Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Keiichiro Miyajima, Akihiro Matsukawa, Takafumi Yanagisawa, Marcin Miszczyk, Navid Roessler, Shota Inoue, Abdulrahman S. Alqahtani, Ahmed R. Alfarhan, Fumihiko Urabe, Keiichiro Mori, Pierre I. Karakiewicz, Takahiro Kimura, Shahrokh F. Shariat
European Urology Open Science.2026; 83: 54. CrossRef
Comparative Outcomes of Surgery and Chemoradiotherapy After Neoadjuvant Chemotherapy in Stage II–III Bladder Cancer
Doğan Bayram, Öznur Bal, Alper Türkel, Serhat Sekmek, Emre Hafızoğlu, Berkan Karabuga, Mutlu Doğan, Efnan Algın, Doğan Uncu
The European Research Journal.2026; 12(2): 160. CrossRef
Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle‐Invasive Bladder Cancer
Tomokazu Kimura, Satoshi Inoue, Tomoyasu Sano, Kenji Zennami, Shusuke Akamatsu
International Journal of Urology.2025; 32(10): 1334. CrossRef
Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Keiichiro Miyajima, Akihiro Matsukawa, Takafumi Yanagisawa, Marcin Miszczyk, Navid Roessler, Shota Inoue, Shingo Nishimura, Abdulrahman S. Alqahtani, Ahmed R. Alfarhan, Fumihiko Urabe, Keiichiro Mori, Pierre I. Karakiewicz, Leonardo Oliveira Reis, Takahir
European Urology Focus.2025;[Epub] CrossRef
Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Keiichiro Miyajima, Shota Inoue, Ahmed R. Alfarhan, Abdulrahman S. Alqahtani, Markus von Deimling, Malte W. Vetterlein, Jeremy Yuen-Chun Teoh, David D’Andrea, Margit Fisch, Shahrokh F. Shariat
World Journal of Urology.2025;[Epub] CrossRef
News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard?
Olivier Riou, Christophe Hennequin, Jonathan Khalifa, Paul Sargos
Cancer/Radiothérapie.2024; 28(6-7): 623. CrossRef

6,215 View
212 Download
5 Web of Science
6 Crossref

Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative Cohort Study: Hang An, Keyang Liu, Kokoro Shirai, Ryo Kawasaki, Akiko Tamakoshi, Hiroyasu Iso; Cancer Res Treat. 2024;56(2):616-623. Published online October 6, 2023; DOI: https://doi.org/10.4143/crt.2023.962

Abstract PDF Supplementary Material PubReader ePub

Purpose
The association of physical activity with the risk of bladder cancer remains inconsistent among Asian populations. We aimed to examine the association in a large Japanese cohort.
Materials and Methods
In a population-based prospective cohort study, a total of 50,374 Japanese adults aged 40-79 years without a history of cancer or cardiovascular disease who had information on physical activity from self-administrated questionnaires were used for analysis. We performed Cox proportional hazard models to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident bladder cancer after adjusting for several potential confounders.
Results
During the median 17.5 years of follow-up, 153 incident bladder cancers (116 men and 37 women) were identified. After the multivariable adjustment, HRs (95% CI) of bladder cancer concerning those with recreational sports participation of 1-2 hr/wk, 3-4 hr/wk, and 5 hr/wk and more were 0.67 (0.38-1.20), 0.79 (0.36-1.74), and 0.28 (0.09-0.89), respectively (p for trend=0.017). Compared with mostly sitting at the workplace, occupational physical activity of standing and walking were associated with a lower risk of bladder cancer (HR, 0.53 [95% CI, 0.32 to 0.85]). Hours of daily walking were not associated with the risk. The lower risk of bladder cancer was more evident for recreational sports (HR, 0.33 [95% CI, 0.10 to 1.00]), and for occupational standing and walking activity at work (HR, 0.57 [95% CI, 0.33 to 0.98]) among men.
Conclusion
Recreational sports participation and occupational physical activity were inversely associated with the risk of bladder cancer among Japanese, especially in men.

Citations

Citations to this article as recorded by

Physical Activity and Cancer Incidence and Mortality: Current Evidence and Biological Mechanisms
Joanna Kruk, Basil Hassan Aboul-Enein, Marta Ewelina Gołębiewska, Ewa Duchnik, Urszula Czerniak, Mariola Marchlewicz
Cancers.2025; 17(9): 1410. CrossRef
Occupational physical activity and incidence and mortality of 14 cancers in 404,249 adults
Cristina Cadenas-Sanchez, Miguel Adriano Sanchez-Lastra, Jakob Tarp, Ulf Ekelund, Knut Eirik Dalene
Nature Communications.2025;[Epub] CrossRef

6,340 View
193 Download
2 Web of Science
2 Crossref

TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort: Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh; Cancer Res Treat. 2023;55(4):1337-1345. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2023.417

Abstract PDF Supplementary Material PubReader ePub

Purpose
Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods
Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results
UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion
Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.

Citations

Citations to this article as recorded by

Urachal Carcinomas: A Comprehensive Systematic Review and Meta-analysis
Caio Vinícius Suartz, Lucas Motta Martinez, Marcelo Henrique Lima Silvestre, Richard Dobrucki de Lima, Pedro Henrique Souza Brito, Ketlyn Assunção Galhardo, Roberto Iglesias Lopes, Victor Hondo Silva de Moraes, Caio Mazzonetto Teofilo de Moraes, Luana Cov
International braz j urol.2025;[Epub] CrossRef
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign
Clinical Genitourinary Cancer.2024; 22(1): 67. CrossRef
Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho
BJUI Compass.2024; 5(3): 327. CrossRef

5,687 View
211 Download
3 Web of Science
3 Crossref

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park; Cancer Res Treat. 2023;55(2):636-642. Published online October 6, 2022; DOI: https://doi.org/10.4143/crt.2022.343

Abstract PDF PubReader ePub

Purpose
The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC).
Materials and Methods
In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety.
Results
Between September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates.
Conclusion
Neoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).

Citations

Citations to this article as recorded by

Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing
Wei Ning, Pengkang Chang, Ji Zheng, Wei Chen
Frontiers in Immunology.2026;[Epub] CrossRef
Advances in the management of localized bladder cancers
Marie-Pier St-Laurent, Jussi Nikkola, Eisuke Tomiyama, Peter C. Black
Nature Reviews Clinical Oncology.2026;[Epub] CrossRef
Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma Using Amide Proton Transfer-Weighted MRI
Lingmin Kong, Bei Weng, Qian Cai, Ling Ma, Wenxin Cao, Yanling Chen, Long Qian, Yan Guo, Junxing Chen, Huanjun Wang
Academic Radiology.2025; 32(4): 2090. CrossRef
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Joaquim Bellmunt, Brian M. Russell, Bernadett Szabados, Begoña P. Valderrama, Rosa Nadal
American Society of Clinical Oncology Educational Book.2025;[Epub] CrossRef
Comparison of neoadjuvant chemotherapy and combined chemotherapy with immunotherapy for muscle-invasive bladder cancer: a propensity score-matched analysis
Hao Zhang
American Journal of Translational Research.2025; 17(1): 125. CrossRef
Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period
Jincong Li, Yuxuan Song, Rui Chen, Hanlin Gao, Yang Liu, Yun Peng, Jilin Wu, Shicong Lai, Yiqing Du, Caipeng Qin, Tao Xu
Annals of Surgical Oncology.2025; 32(8): 6141. CrossRef
The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer
Joseph Kattan, Clarisse Kattan, Fouad Aoun, Elie Nemr
Frontiers in Oncology.2025;[Epub] CrossRef
Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update
Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Konstantinos Tzelepis, Zisis Kratiras, Evangelos Fragkiadis, Ioannis Zachos, Vasileios Tzortzis, Michael Chrisofos, Nikolaos Charalampakis
Immunotherapy.2025; 17(6): 447. CrossRef
Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors
Xinya Wang, Qin Zhou, Xuyan Zhang, Han Hu, Binlei Liu, Yang Wang
Frontiers in Immunology.2025;[Epub] CrossRef
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates
Takafumi Yanagisawa, Akihiro Matsukawa, Jeremy Yuen-Chun Teoh, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Paweł Rajwa, Fahad Quhal, Benjamin Pradere, Marco Moschini, Shahrokh F. Shariat, Jun Miki, Takahiro Kimura
Bladder Cancer.2025;[Epub] CrossRef
Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis
Akihiro Matsukawa, Angelo Cormio, Marcin Miszczyk, Mehdi Kardoust Parizi, Tamás Fazekas, Ichiro Tsuboi, Stefano Mancon, Robert J. Schulz, Giulio Litterio, Ekaterina Laukhtina, Paweł Rajwa, Thomas Seisen, Keiichiro Mori, Francesca Sanguedolce, Andrea Bened
European Urology Oncology.2025; 8(6): 1673. CrossRef
Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
Shugo Yajima, Naoki Imasato, Hitoshi Masuda
BJUI Compass.2025;[Epub] CrossRef
Optimizing enfortumab vedotin plus pembrolizumab therapy
Elias Antoine Karam, Yaghi César Céline, Gilles Prince, Fouad Attieh, Hampig Raphael Kourie, Joseph Kattan, Elie Nemer
Oncotarget.2025; 16(1): 481. CrossRef
Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A Meta-Analysis
Lian Hu, Jia-Wei Hu, Chang-Quan Wang, Rui-Ying Li, Song Li
Clinical Genitourinary Cancer.2025; 23(5): 102408. CrossRef
Muscle-Invasive Bladder Cancer: A Watershed Moment
Matthew D. Galsky, Leslie Ballas, Ashish M. Kamat
Journal of Clinical Oncology.2025; 43(27): 3041. CrossRef
Current Status and Future Perspectives of Immunotherapies in Bladder Cancer
Gökhan Çolak, Bilgin Demir
Acta Haematologica Oncologica Turcica.2025;[Epub] CrossRef
Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Keiichiro Miyajima, Shota Inoue, Ahmed R. Alfarhan, Abdulrahman S. Alqahtani, Markus von Deimling, Malte W. Vetterlein, Jeremy Yuen-Chun Teoh, David D’Andrea, Margit Fisch, Shahrokh F. Shariat
World Journal of Urology.2025;[Epub] CrossRef
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Shibo Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Raoshan Luo, Weiming Liang
Frontiers in Immunology.2024;[Epub] CrossRef
What’s new about the tumor microenvironment of urothelial carcinoma?
João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões, Sérgio Xavier Azevedo, Joana Febra, António Araújo
Clinical and Translational Oncology.2024; 26(7): 1549. CrossRef
A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues
Yi Huang, Chengxiao Liao, Zefeng Shen, Yitong Zou, Weibin Xie, Qinghua Gan, Yuhui Yao, JunJiong Zheng, Jianqiu Kong
Frontiers in Immunology.2024;[Epub] CrossRef
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
Clinical and Translational Oncology.2024; 26(7): 1759. CrossRef
Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Cancer Research and Treatment.2024; 56(3): 893. CrossRef
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, M
New England Journal of Medicine.2024; 391(19): 1773. CrossRef
Klassische Chemotherapie, Immuntherapie oder adjuvante Strahlentherapie – Wie können wir die onkologischen Ergebnisse der radikalen Zystektomie verbessern?
Pia Paffenholz, Stefanie Zschäbitz
Die Urologie.2024; 63(10): 994. CrossRef
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer
Jan-Jaap J. Mellema, Bas W.G. van Rhijn, Michiel S. van der Heijden
Current Opinion in Urology.2023; 33(5): 404. CrossRef

9,566 View
315 Download
21 Web of Science
25 Crossref

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy: Ryul Kim, Jung Yong Hong, Jeeyun Lee, Ghee Young Kwon, Byong Chang Jeong, Se Hoon Park; Cancer Res Treat. 2022;54(3):894-906. Published online November 17, 2021; DOI: https://doi.org/10.4143/crt.2021.854

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI).
Materials and Methods
We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8).
Results
We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1–positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1–negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1–positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1–positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment.
Conclusion
Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.

Citations

Citations to this article as recorded by

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Areti Strati, Christos Adamopoulos, Ioannis Kotsantis, Amanda Psyrri, Evi Lianidou, Athanasios G. Papavassiliou
International Journal of Molecular Sciences.2025; 26(3): 1235. CrossRef
Development of a Technique for Diagnosis and Screening of Superficial Bladder Cancer by Cell-Pellet DNA From Urine Sample
Jaekwon Seok, Hee Jeong Kwak, Chan-Koo Kang, Ah Ram Kim, Woo Suk Choi, Hyoung Keun Park, Sung Hyun Paick, Hyeong Gon Kim, Yeonjoo Kwak, Tak-Il Jeon, Kyung Min Lim, Baeckseung Lee, Aram Kim, Ssang-Goo Cho
Laboratory Investigation.2025; 105(6): 104124. CrossRef
Sex-Specific Associations of Glycemic Status and Smoking with Bladder Cancer Risk: A Nationwide Cohort Study
Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen
Cancers.2025; 17(13): 2262. CrossRef
The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy
Li-Juan Chen, Xin-Yang Xu, Xiao-Dan Zhong, Yan-Jun Liu, Ming-Hui Zhu, Fan Tao, Chang-Yun Li, Qiu-Sheng She, Guan-Jun Yang, Jiong Chen
Bioorganic Chemistry.2023; 133: 106409. CrossRef
A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma
Zheng Zhou, Yusong Zhou, Wei Liu, Jing Dai
Frontiers in Genetics.2023;[Epub] CrossRef
Implication of KDM6A in Bladder Cancer
Marianne Matar, Gilles Prince, Ibrahim Hamati, Maria Baalbaky, Jonas Fares, Marc Aoude, Charbel Matar, Hampig Raphael Kourie
Pharmacogenomics.2023; 24(9): 509. CrossRef
Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Biomedicines.2022; 10(8): 2005. CrossRef
Antineoplastics

Reactions Weekly.2022; 1933(1): 61. CrossRef
Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma
Tongjin Xie, Bin Liu, Dongbo Liu, Yusong Zhou, Qingping Yang, Dai Wang, Mengjie Tang, Wei Liu
Frontiers in Pharmacology.2022;[Epub] CrossRef

9,512 View
253 Download
8 Web of Science
9 Crossref

Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis: Jungyo Suh, Dohyun Han, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong; Cancer Res Treat. 2022;54(3):882-893. Published online October 9, 2021; DOI: https://doi.org/10.4143/crt.2021.642

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to identify, verify, and validate a multiplex urinary biomarker-based prediction model for diagnosis and surveillance of urothelial carcinoma of bladder, using high-throughput proteomics methods.
Materials and Methods
Label-free quantification of data-dependent and data-independent acquisition of 12 and 24 individuals was performed in each of the discovery and verification phases using mass spectrometry, simultaneously using urinary exosome and proteins. Based on five scoring system based on proteomics data and statistical methods, we selected eight proteins. Enzyme-linked immunosorbent assay on urine from 120 patients with bladder mass lesions used for validation. Using multivariable logistic regression, we selected final candidate models for predicting bladder cancer.
Results
Comparing the discovery and verification cohorts, 38% (50/132 exosomal differentially expressed proteins [DEPs]) and 44% (109/248 urinary DEPs) are consistent at statistically significance, respectively. The 20 out of 50 exosome proteins and 27 out of 109 urinary proteins were upregulated in cancer patients. From eight selected proteins, we developed two diagnostic models for bladder cancer. The area under the receiver operating characteristic curve (AUROC) of two models were 0.845 and 0.842, which outperformed AUROC of urine cytology.
Conclusion
The results showed that the two diagnostic models developed here were more accurate than urine cytology. We successfully developed and validated a multiplex urinary protein-based prediction, which will have wide applications for the rapid diagnosis of urothelial carcinoma of the bladder. External validation for this biomarker panel in large population is required.

Citations

Citations to this article as recorded by

Extracellular vesicles in tumor microenvironment modulation and clinical diagnosis
Huan Liu, Dong Niu, Tong-Yao Yu, Yu-Hua Wang, Kun-Lin Ran, Yan-Hua Liu, Da-Chuan Yin, Chen-Yan Zhang
Pathology - Research and Practice.2026; 278: 156339. CrossRef
Recent implementations of data-independent acquisition for cancer biomarker discovery in biological fluids
Annie Ha, Michael Woolman, Matthew Waas, Meinusha Govindarajan, Thomas Kislinger
Expert Review of Proteomics.2025; 22(4): 163. CrossRef
Intervention of machine learning in bladder cancer research using multi-omics datasets: systematic review on biomarker identification
Blessy Kiruba, P. S. Athul Narayan, Badhari Raj, S. Rohieth Raj, Sam George Mathew, Sudhakaran Sajitha Lulu, Vino Sundararajan
Discover Oncology.2025;[Epub] CrossRef
A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
eLife.2024;[Epub] CrossRef
A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
eLife.2024;[Epub] CrossRef
Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer
Qi Chang, Yongqiang Chen, Jianjian Yin, Tao Wang, Yuanheng Dai, Zixin Wu, Yufeng Guo, Lingang Wang, Yufen Zhao, Hang Yuan, Dongkui Song, Lirong Zhang
Journal of Proteome Research.2024; 23(6): 2241. CrossRef
Construction of noninvasive prognostic model of bladder cancer patients based on urine proteomics and screening of natural compounds
Shun Wan, Jinlong Cao, Siyu Chen, Jianwei Yang, Huabin Wang, Chenyang Wang, Kunpeng Li, Li Yang
Journal of Cancer Research and Clinical Oncology.2023; 149(1): 281. CrossRef
Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
Ana Teixeira-Marques, Catarina Lourenço, Miguel Carlos Oliveira, Rui Henrique, Carmen Jerónimo
International Journal of Molecular Sciences.2023; 24(7): 6757. CrossRef
Advances in the application of label‐free quantitative proteomics techniques in malignancy research
Xiao Meng, Dong Liu, Yan Guan
Biomedical Chromatography.2023;[Epub] CrossRef
Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer
Jiaxin Zhao, Jinming Li, Rui Zhang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(4): 188926. CrossRef
An overview of metabolomic and proteomic profiling in bipolar disorder and its clinical value
Henrique Caracho Ribeiro, Flávia da Silva Zandonadi, Alessandra Sussulini
Expert Review of Proteomics.2023; 20(11): 267. CrossRef
Proteome and immune responses of extracellular vesicles derived from macrophages infected with the periodontal pathogen Tannerella forsythia
Younggap Lim, Hyun Young Kim, Dohyun Han, Bong‐Kyu Choi
Journal of Extracellular Vesicles.2023;[Epub] CrossRef
A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers
Milena Matuszczak, Adam Kiljańczyk, Maciej Salagierski
International Journal of Molecular Sciences.2022; 23(15): 8597. CrossRef
Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19
Takahiro Kawasaki, Yoshito Takeda, Ryuya Edahiro, Yuya Shirai, Mari Nogami-Itoh, Takanori Matsuki, Hiroshi Kida, Takatoshi Enomoto, Reina Hara, Yoshimi Noda, Yuichi Adachi, Takayuki Niitsu, Saori Amiya, Yuta Yamaguchi, Teruaki Murakami, Yasuhiro Kato, Tak
Inflammation and Regeneration.2022;[Epub] CrossRef

10,853 View
310 Download
14 Web of Science
14 Crossref

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery: Hyehyun Jeong, Kye Jin Park, Yongjune Lee, Hyung-Don Kim, Jwa Hoon Kim, Shinkyo Yoon, Bumsik Hong, Jae Lyun Lee; Cancer Res Treat. 2022;54(1):226-233. Published online May 6, 2021; DOI: https://doi.org/10.4143/crt.2021.365

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aims to evaluate the prognosis of pathologically node-positive bladder cancer after neoadjuvant chemotherapy, the role of adjuvant chemotherapy in these patients, and the value of preoperative clinical evaluation for lymph node metastases.
Materials and Methods
Patients who received neoadjuvant chemotherapy followed by partial/radical cystectomy and had pathologically confirmed lymph node metastases between January 2007 and December 2019 were identified and analyzed.
Results
A total of 53 patients were included in the study. The median age was 61 years (range, 34 to 81 years) with males comprising 86.8%. Among the 52 patients with post-neoadjuvant/pre-operative computed tomography results, only 33 patients (63.5%) were considered positive for lymph node metastasis. Sixteen patients (30.2%) received adjuvant chemotherapy (AC group), and 37 patients did not (no AC group). With the median follow-up duration of 67.7 months, the median recurrence-free survival (RFS) and the median overall survival (OS) was 8.5 months and 16.2 months, respectively. The 2-year RFS and OS rates were 23.3% and 34.6%, respectively. RFS and OS did not differ between the AC group and no AC group (median RFS, 8.8 months vs. 6.8 months, p=0.772; median OS, 16.1 months vs. 16.3 months, p=0.479). Thirty-eight patients (71.7%) experienced recurrence. Distant metastases were the dominant pattern of failure in both the AC group (91.7%) and no AC group (76.9%).
Conclusion
Patients with lymph node-positive disease after neoadjuvant chemotherapy followed by surgery showed high recurrence rates with limited survival outcomes. Little benefit was observed with the addition of adjuvant chemotherapy.

Citations

Citations to this article as recorded by

A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy
Garrett K. Harada, Steven N. Seyedin, Olivia Heutlinger, Armon Azizi, Audree Hsu, Arash Rezazadeh, Michael Daneshvar, Greg E. Gin, Edward M. Uchio, Giovanna A. Giannico, Jeremy P. Harris, Aaron B. Simon, Jeffrey V. Kuo, Nataliya Mar
Advances in Radiation Oncology.2025; 10(1): 101671. CrossRef
Resultados oncológicos de pacientes con afectación ganglionar tras quimioterapia neoadyuvante y cistectomía radical para el cáncer de vejiga músculo-invasivo: estudio observacional multicéntrico del Grupo de Trabajo de Carcinoma Urotelial de la sección de
G. Marcq, W. Kassouf, M. Roumiguié, B. Pradere, L.S. Mertens, S. Albisinni, A. Cimadamore, J. Yuen-Chun Teoh, M. Moschini, E. Laukhtina, A. Mari, F. Soria, A. Gallioli, F. del Giudice, D. d’Andrea, W. Krajewski, J.B. Beauval, E. Xylinas, D. Pouessel, P. S
Actas Urológicas Españolas.2025; 49(2): 501701. CrossRef
Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma wor
G. Marcq, W. Kassouf, M. Roumiguié, B. Pradere, L.S. Mertens, S. Albisinni, A. Cimadamore, J. Yuen-Chun Teoh, M. Moschini, E. Laukhtina, A. Mari, F. Soria, A. Gallioli, F. del Giudice, D. d’Andrea, W. Krajewski, J.B. Beauval, E. Xylinas, D. Pouessel, P. S
Actas Urológicas Españolas (English Edition).2025; 49(2): 501701. CrossRef
Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An International Multi-Institutional Study Comparing Isolated Nodal Disease vs Persistent Muscle-Invasive Disease
Andres M. Acosta, Mohammed Saad, Alcides Chaux, Jennifer B. Gordetsky, Lan Zheng, Charles Guo, Mohamed Bikhet, Adeboye O. Osunkoya, Katrina Collins, Muhammad T. Idrees, Geert J.L.H. van Leenders, Pilar Gonzalez-Peramato, Kristine M. Cornejo, Michelle S. H
Urology.2025; 200: 127. CrossRef
Demonstrating the non-inferiority of robotic radical cystectomy for cT3–cT4 urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity score-matched analysis
Il Woo Park, Tae Il Noh, Seok Ho Kang, Jong Jin Oh, Seung Hwan Jeong, Won Sik Ham, Jieun Heo, Hyun Hwan Sung, Byong Chang Jeong, Geehyun Song, Ho Kyung Seo, Kyung Hwan Kim, Jong Kil Nam, Wook Nam, Yun-Sok Ha, Joongwon Choi, Wan Song, Bumjin Lim
Journal of Robotic Surgery.2025;[Epub] CrossRef
Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes
Krystian Kaczmarek, Bartosz Małkiewicz, Karolina Skonieczna-Żydecka, Artur Lemiński
Cancers.2023; 15(19): 4901. CrossRef
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Serhat Sekmek, Gökhan Ucar, Irfan Karahan, Dogan Bayram, Selin Aktürk Esen, Ismet Seven, Mehmet Ali Nahit Sendur, Dogan Uncu
African Journal of Urology.2023;[Epub] CrossRef

7,941 View
192 Download
6 Web of Science
7 Crossref

Case Report

Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread: Hyun Sik Park, Hyun Bin Shin, Myung-Shin Lee, Joo Heon Kim, Seon-Young Kim, Jinsung Park; Cancer Res Treat. 2020;52(4):1283-1287. Published online March 19, 2020; DOI: https://doi.org/10.4143/crt.2020.002

Abstract PDF Supplementary Material PubReader ePub: We present a rare case of urothelial carcinoma in situ (CIS), which invades the prostate and seminal vesicle (SV). A 70-year-old man underwent transurethral resection of bladder (TURB), and the pathologic examination revealed multiple CIS. Although the patient received intravesical bacillus Calmette-Guerin (BCG) therapy following TURB, recurrence of CIS was confirmed in the bladder and left distal ureter at 3 months following BCG. Radical cystectomy was performed due to BCG-refractory CIS. Microscopically, CIS was found throughout the mucosa of the bladder, left ureter, prostatic duct, and both SVs. Next-generation sequencing revealed significant differences in tumor clonality between bladder and SV CIS cells. Among 101 (bladder CIS) and 95 (SV CIS) somatic mutations, only two were shared, and only one gene (ARHGAP23) was common exon coding region gene. In conclusion, multicentric genetic changes, in line with the field-cancerization effect, may result in SV involvement by CIS of the bladder.

7,096 View
138 Download
1 Web of Science

Original Articles

Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea: Ji Sung Shim, Ho Kyung Seo, Ja Hyeon Ku, Byong Chang Jeong, Bumsik Hong, Seok Ho Kang, UCART (Urothelial Cancer-Advanced Research and Treatment Group in Korea) Group; Cancer Res Treat. 2019;51(3):1064-1072. Published online October 30, 2018; DOI: https://doi.org/10.4143/crt.2018.515

Abstract PDF PubReader ePub

Purpose
The lower incidence of bladder cancer among women has led to a lack of information on female radical cystectomy (RC). This study aimed to analyze the characteristics related with female RC in a cohort from multiple academic institutions.
Materials and Methods
This was a retrospective review of 384 female patients who underwent RC for bladder cancer. Epidemiologic, perioperative variables including urologic referral periodwith consequent pathologic stage distributions were assessed. The changes in surgical techniques over time were illustrated. Also, we evaluated recurrence-free survival (RFS) at 2 and 5 years and overall survival (OS) at 5 years with stage-specific analyses using the Kaplan-Meier method.
Results
The mean follow-up time was 35 months (interquartile rage [IQR], 9 to 55). The average time to urologic referral with initial symptoms was 5.5 (IQR, 1 to 6) months and over 20% of patients visited clinics after 6 months. In subsequent stage distributions according to referral period, T2 or higher stage distributions were abruptly increased after 1 year. Overall 2-year/5-year RFS rates were 0.72/0.57 and 5-year OS was 0.61. Notable surgical descriptions were as follows: 91% of patients underwent open RC; 80% of patients underwent an ileal conduit; and 83% of patients received anterior exenteration. However, the proportions of robotic surgery, orthotopic neobladder and organ sparing cystectomy have increased recen-tly.
Conclusion
We identified the general characteristics and changes in pattern of female RC. Our results also suggest that women are susceptible to delays in referral to an urologist and are at greater risk for worse prognosis.

Citations

Citations to this article as recorded by

Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer
Federico Ceria, Gad Muhammad, Francesco Del Giudice, Youssef Ibrahim, Ramesh Thurairaja, Rajesh Nair, Elsie Mensah, Muhammad Shamim Khan, Yasmin Abu Ghanem
Cancers.2026; 18(2): 308. CrossRef
Optimizing local control in the surgical management of bladder cancer
Martin Egger, Vincent D. D’Andrea, Clara Steiner, Nnamdi O. Onochie, Timothy N. Clinton, Chong-Xian Pan, Adam S. Kibel, Cheryl T. Lee, Kent W. Mouw, Matthew Mossanen
Nature Reviews Urology.2025;[Epub] CrossRef
Perioperative, oncological, and survival outcomes of robotic radical cystectomy with urinary diversion in females
Varun V. Agarwal, B. Yuvaraja Thyavihally, Santosh Subhash Waigankar, Preetham Dev, Abhinav P. Pednekar, Diptiman Roy, Nevitha Athikari, Meenal Hastak, Naresh Badlani, D. Harshwardhan Pokharkar, Nagaraja Sekhar Ayyalasomayajula, Archan Khandekar, Ashish A
Indian Journal of Urology.2023; 39(1): 27. CrossRef
Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
Sunil H. Patel, Shirley Wang, Meredith R. Metcalf, Natasha Gupta, Andrew Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine Smith, Noah Hahn, Mark Schoenberg, Max Kates, Jean Hoffman-Censits, Trinity J. Bivalacqua
Clinical Genitourinary Cancer.2022; 20(1): 60. CrossRef
The learning curve for robot-assisted radical cystectomy with total intracorporeal urinary diversion based on radical cystectomy pentafecta
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jong Hyun Pyun, Seok Ho Kang
Frontiers in Oncology.2022;[Epub] CrossRef

8,780 View
146 Download
5 Web of Science
5 Crossref

Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population: Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park; Cancer Res Treat. 2019;51(1):289-299. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.053

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population.
Materials and Methods
Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9.
Results
There was no significant difference between the groups in terms of any of the functioning sub-scales and symptoms, except significantly lower social functioning observed in BC survivors than that observed in KC survivors. Although the three groups of UC survivors showed essentially similar functioning sub-scales and symptoms when compared to the general population, PC and BC survivors showed significantly lower social functioning and a lower appetite than that observed in controls. KC survivors showed lower physical functioning, as well as higher pain and dyspnea. Although all three groups of UC survivors reported higher financial difficulties, they also reported higher perceived social support than that reported by the non-cancer control group. No statistically significant difference was observed in terms of depressive symptoms between each group of UC survivors and the general population.
Conclusion
Disease-free survivors of the three major types of UCs showed generally similar HRQoL compared to the general population, as well as compared to each other.

Citations

Citations to this article as recorded by

Diagnostic Yield of Fusion-Guided and Randomized Biopsies in Prostate Cancer: Evidence for an Integrated Approach
Osama Salloum, Iulian-Alexandru Taciuc, Alexandru Dick, Costin Petcu, Costin Gingu, Nicoleta Sanda, Andreea Nicoleta Marinescu, Crenguta Serboiu, Adrian Costache
Healthcare.2025; 13(17): 2214. CrossRef
Investigating the relationships between social support and hospital anxiety- depression with quality of life in geriatric cancer outpatients under oncology treatments
Nahid Jamshidi, Fatemeh Mehravar, Mahtab Alizadeh-Khoei, Farnaz Etesam
BMC Geriatrics.2025;[Epub] CrossRef
Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder
So Hee Kim, Eunjung Ryu, Byong Chang Jeong
Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100490. CrossRef
The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score‐matched study
Giuseppe Palermo, Francesco Pio Bizzarri, Eros Scarciglia, Emilio Sacco, Koosha Moosavi Seyed, Pierluigi Russo, Filippo Gavi, Giovanni Battista Filomena, Francesco Rossi, Marco Campetella, Angelo Totaro, Nazario Foschi, Marco Racioppi
International Journal of Urology.2024; 31(12): 1423. CrossRef
Factors Affecting the Health-Related Quality of Life of Patients with Bladder Cancer
Haetsal Kwon, Hyojung Park
Journal of Korean Public Health Nursing.2024; 38(3): 358. CrossRef
Properties of the Shift and Persist Questionnaire in adolescent and young adult cancer patients and survivors: Validity, consistency, and interpretability
Karly M. Murphy, Edith Chen, Edward H. Ip, Abby R. Rosenberg, Mallory A. Snyder, John M. Salsman
Quality of Life Research.2023; 32(1): 273. CrossRef
Adoption of patient communication rules in clinical practice and the role of faith-based communities in shaping them: the palliative aspect of spiritual support
Konstantin Sokolovskiy, Olga Pashanova, Vladimir Beketov, Andrey Aleshkin
Mental Health, Religion & Culture.2023; 26(1): 16. CrossRef
Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review
Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson
Journal of Cancer Survivorship.2022; 16(6): 1279. CrossRef
Mental Health in Urologic Oncology
Danyon Anderson, Abrahim N. Razzak, Matthew McDonald, David Cao, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits
Health Psychology Research.2022; 10(3): 1. CrossRef
Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review
Liliana Vartolomei, Manuela Schmidinger, Mihai Vartolomei, Shahrokh Shariat
Journal of Clinical Medicine.2022; 11(21): 6383. CrossRef
Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status
Kisook Kim, Hyohyeon Yoon
International Journal of Environmental Research and Public Health.2021; 18(7): 3803. CrossRef
Feasibility of a socio-spiritual intervention to improve quality of life of adult Nigerians with cancer and their family caregivers: Protocol for a randomised controlled trial
Israel Gabriel, Debra Creedy, Elisabeth Coyne
Contemporary Clinical Trials Communications.2021; 22: 100802. CrossRef
Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker
Supportive Care in Cancer.2020; 28(6): 2875. CrossRef
Comorbid depression in medical diseases
Stefan M. Gold, Ole Köhler-Forsberg, Rona Moss-Morris, Anja Mehnert, J. Jaime Miranda, Monika Bullinger, Andrew Steptoe, Mary A. Whooley, Christian Otte
Nature Reviews Disease Primers.2020;[Epub] CrossRef
Health-related Quality of Life and Its Related Factors among Cancer Survivors and General Adults: Focusing on Lifestyle Behaviors and Mental Health
Eun A Song, Youngran Kweon, Yoon Young Hwang, Minjeong An
Korean Journal of Adult Nursing.2020; 32(4): 385. CrossRef
Age and gender differences in anxiety and depression in cancer patients compared with the general population
Andreas Hinz, Philipp Yorck Herzberg, Florian Lordick, Joachim Weis, Hermann Faller, Elmar Brähler, Martin Härter, Karl Wegscheider, Kristina Geue, Anja Mehnert
European Journal of Cancer Care.2019;[Epub] CrossRef

13,971 View
221 Download
14 Web of Science
16 Crossref

Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24: Jinsung Park, Dong Wook Shin, Tae-Hwan Kim, Seung Il Jung, Jong Kil Nam, Seung Chol Park, Sungwoo Hong, Jae Hung Jung, Hongwook Kim, Won Tae Kim; Cancer Res Treat. 2018;50(1):40-49. Published online March 10, 2017; DOI: https://doi.org/10.4143/crt.2016.594

Abstract PDF PubReader ePub

Purpose
We aimed to evaluate psychometric properties of the Korean version of the EORTC QLQ-NMIBC24 when applied to Korean non-muscle invasive bladder cancer (NMIBC) patients.
Materials and Methods
A total of 249 patients who underwent curative transurethral resection of bladder tumor (TURBT) for primary orrecurrentNMIBCwere asked to complete theKorean version of EORTC QLQ-C30 and -NMIBC24 questionnaires three times (preoperative, post-TURBT 3 months and 6 months). Linguistic validation and psychometric evaluation of the questionnaire was conducted.
Results
Multitrait scaling analysis confirmed satisfactory construct validity in five scales except the malaise scale. Internal consistency was good (Cronbach’s alpha ≥ 0.70) for the five scales except the malaise scale at the all three time points. Known-group comparison analyses showed better quality-of-life (QOL) scores in patients with higher performance status as expected, and better sexual function in men than women (p < 0.05). Most of the scales had low correlations (< 0.40) with the scales in QLQ-C30 showing divergent validity, except for malaise scale which showed higher correlations (0.42 to 0.60). Responsiveness to change was consistent with clinical implications over time after TURBT.
Conclusion
The Korean version of the EORTC QLQ-NMIBC24 has good reliability and cross-cultural validity for measuring various QOL aspects that can be self-administered to Korean NMIBC patients undergoing TURBT.

Citations

Citations to this article as recorded by

Comprehensive nursing care for advanced digestive malignancy patients during chemotherapy based on probiotic intervention: a randomized controlled study on improvement of gastrointestinal function and prevention of complications
Feng Huang, Qi Zhuo, Lijuan Zhang, Zheng Gao, Chennuo He, Lanlan Zhang
Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Health-related Quality of Life During the First 4 Years After Non–Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort
Ivy Beeren, Nena E. Klerks, Katja K. Aben, Jorg R. Oddens, J. Alfred Witjes, Lambertus A. Kiemeney, Alina Vrieling
European Urology Oncology.2024; 7(4): 829. CrossRef
Transurethral resection of bladder tumor with Bacille Calmette-Guerin intravesical instillation for HRNMIBC and factors influencing recurrence
An Xu
American Journal of Translational Research.2024; 16(11): 6914. CrossRef
The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review
E. Rammant, L. Fox, K. Beyer, N. K. Aaronson, R. Chaloner, S. De Padova, F. Liedberg, L. M. Wintner, K. Decaestecker, V. Fonteyne, N. Perdek, H. Wylie, J. W. F. Catto, T. M. Ripping, B. Holzner, M. Van Leeuwen, M. Van Hemelrijck
Quality of Life Research.2023; 32(8): 2127. CrossRef
Quality of life in bladder cancer: systematic review and meta-analysis
Sima Rafiei, Golnaz Kheradkhah, Grigorios Kotronoulas, Maryam Doustmehraban, Farnoosh Shafiei, Maryam Masoumi, Elaheh Parnian, Elmira Nosrati Sanjabad, Ahmad Ghashghaee
BMJ Supportive & Palliative Care.2023; 13(e3): e707. CrossRef
Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis
Jeongok Park, Young Deuk Choi, Kyoungjin Lee, Miae Seo, Ahyoung Cho, Sejeong Lee, Keum-hee Nam
Asia-Pacific Journal of Oncology Nursing.2022; 9(6): 100063. CrossRef
Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer
T. M. Ripping, E. Rammant, J. A. Witjes, N. K. Aaronson, M. van Hemelrijck, L. M. C. van Hoogstraten, J. Boormans, C. A. Goossens, A. G. van der Heijden, M. C. C. M. Hulshof, G. J. L. H. van Leenders, A. M. van Leliveld, R. P. Meijer, R. J. A. van Moorsel
Health and Quality of Life Outcomes.2022;[Epub] CrossRef
Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
Theodora M. Ripping, Ellen Westhoff, Neil K. Aaronson, Mieke Van Hemelrijck, Elke Rammant, J. Alfred Witjes, Lambertus. A. Kiemeney, Katja K. H. Aben, Alina Vrieling
Journal of Patient-Reported Outcomes.2021;[Epub] CrossRef
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews

Lauren J Lee, Christina S Kwon, Anna Forsythe, Carla M Mamolo, Elizabeth T Masters, Ira A Jacobs
ClinicoEconomics and Outcomes Research.2020; Volume 12: 693. CrossRef
Effect of a patient education and rehabilitation program on anxiety, depression and quality of life in muscle invasive bladder cancer patients treated with adjuvant chemotherapy
Zhonghui Li, Dan Wei, Chenxi Zhu, Qing Zhang
Medicine.2019; 98(44): e17437. CrossRef

10,696 View
310 Download
14 Web of Science
10 Crossref

TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling: Shu-Tao Tan, Sheng-Ye Liu, Bin Wu; Cancer Res Treat. 2016;48(4):1302-1312. Published online March 11, 2016; DOI: https://doi.org/10.4143/crt.2015.381

Abstract PDF PubReader ePub

Purpose
TRIM29 overexpression has been reported in several human malignancies and showed correlation with cancer cell malignancy. The aim of the current study is to examine its clinical significance and biological roles in human bladder cancer tissues and cell lines. Materials and Methods A total of 102 cases of bladder cancer tissues were examined for TRIM29 expression by immunohistochemistry. siRNA and plasmid transfection were performed in 5637 and BIU- 87 cell lines. Cell Counting Kit-8, flow cytometry, western blot, and real-time polymerase chain reaction were performed to examine its biological roles and mechanism in bladder cancer cells.
Results
We found that TRIM29 overexpression showed correlation with invading depth (p=0.0087). Knockdown of TRIM29 expression in bladder cancer cell line 5637 inhibited cell growth rate and cell cycle transition while its overexpression in BIU-87 cells accelerated cell proliferation and cell cycle progression. TRIM29 overexpression also inhibited cell apoptosis induced by cisplatin. In addition, we demonstrated that TRIM29 depletion decreased while its overexpression led to upregulated expression of cyclin D1, cyclin E, and Bcl-2. We also showed that TRIM29 knockdown inhibited protein kinase C (PKC) and nuclear factor κB (NF-κB) signaling while its overexpression stimulated the PKC and NF-κB pathways. BAY 11-7082 (NF-κB inhibitor) partly attenuated the effect of TRIM29 on expression of cyclin and Bcl-2. Treatment with PKC inhibitor staurosporine resulted in ameliorated TRIM29 induced activation of NF-κB. Conclusion The current study demonstrated that TRIM29 upregulates cyclin and Bcl family proteins level to facilitate malignant cell growth and inhibit drug-induced apoptosis in bladder cancer, possibly through PKC–NF-κB signaling pathways.

Citations

Citations to this article as recorded by

TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond
Qitong Wu, Deeptashree Nandi, Dipali Sharma
Cancer and Metastasis Reviews.2025;[Epub] CrossRef
Role of TRIM29 in disease: What is and is not known
Kunying Lv, Qilong Li, Ning Jiang, Qijun Chen
International Immunopharmacology.2025; 147: 113983. CrossRef
TRIM29 promotes liver metastasis via enhancing hepatic colonization by stabilizing FAM83H to regulate keratin network in colorectal cancer
Yang Fu, Runqing Huang, Ge Qin, Shishi Huang, Jianxia Li, Weixiang Zhan, Fan Bai, Xiaoyu Xie, Jiayu Ling, Yue Cai, Yuqian Xie, You Wu, Runkai Cai, Xinrun Huang, Yanhong Deng
Cellular Signalling.2025; 134: 111871. CrossRef
TRIM29 upregulation contributes to chemoresistance in triple negative breast cancer via modulating S100P-β-catenin axis
Qitong Wu, Sumit Siddharth, Deepak Verma, Sheetal Parida, Dipali Sharma
Cell Communication and Signaling.2025;[Epub] CrossRef
Targeting the NF-κB Pathway in Cancer: Mechanisms, Resistance, and Therapeutic Potential Across Tumor Types
Kara Lukas, Jessica Nguyen, Clare Necas, Kushal Dave, Vishwanath Venketaraman
Pharmaceuticals.2025; 18(11): 1764. CrossRef
Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis
Yingzi Li, Lanfang Chen, Qiaochong Zheng, Guanxin Liu, Mengjiao Wang, Shupei Wei, Tao Chen
Molecular Biology Reports.2024;[Epub] CrossRef
Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis via Binding RAD50
Min Wu, Meng-Meng Jin, Xiao-Hui Cao, Lei Zhao, Yong-Huai Li
Current Cancer Drug Targets.2024; 24(4): 445. CrossRef
20-hydroxyecdysone suppresses bladder cancer progression via inhibiting USP21: A mechanism associated with deubiquitination and degradation of p65
Qiang Ma, Fei Wu, Xiaohui Liu, Cuifang Zhao, Yang Sun, Yuanyuan Li, Wei Zhang, Hongge Ju, Yukun Wang
Translational Oncology.2024; 45: 101958. CrossRef
The Role and Mechanism of TRIM Proteins in Gastric Cancer
Wangxi Wu, Jinyu Yang, Tian Yu, Zhuoling Zou, Xuan Huang
Cells.2024; 13(24): 2107. CrossRef
Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape
Junjie Gu, Jingyi Chen, Shuaixi Xiang, Xikun Zhou, Jing Li
Journal of Advanced Research.2023; 54: 147. CrossRef
TRIM29 promotes podocyte pyroptosis in diabetic nephropathy through the NF‐kB/NLRP3 inflammasome pathway
Xiaohong Xu, Zihan Qin, Ce Zhang, Xia Mi, Chi Zhang, Feihong Zhou, Junsheng Wang, Liexiang Zhang, Fei Hua
Cell Biology International.2023; 47(6): 1126. CrossRef
Potential implications of protein kinase Cα in pathophysiological conditions and therapeutic interventions
Rishi Kant Singh, Sanjay Kumar, Sandeep Kumar, Alok Shukla, Naveen Kumar, Anand Kumar Patel, Lokesh Kumar Yadav, Kaushalendra, Meera Antiwal, Arbind Acharya
Life Sciences.2023; 330: 121999. CrossRef
TRIM29 promotes the progression of colorectal cancer by suppressing EZH2 degradation
Yuanjian Chen, Jun Ma, Mingming Zhang
Experimental Biology and Medicine.2023; 248(18): 1527. CrossRef
TRIM14 and TRIM29 as potential tumor markers for breast cancer diagnosis
Mohammadreza Roshanazadeh, mojtaba rashidi, Arash sanaei, Hossein azizi dariuni, amirnader emami razavi, Maryam Adelipour
Journal of Breast Disease.2023; 16(4): 4. CrossRef
TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer
Huai-Yu Qiao, Qi Zhang, Jia-Mei Wang, Jing-Yi Jiang, Ling-Yue Huyan, Jing Yan, Chao Li, Hua-Qin Wang
Cancer Letters.2022; 529: 85. CrossRef
NCAPG promotes tumorigenesis of bladder cancer through NF-κB signaling pathway
Feng Tang, Hua Yu, Xia Wang, Jiageng Shi, Zhizhuang Chen, Hao Wang, Ziyu Wan, Qiqi Fu, Xuan Hu, Yisha Zuhaer, Tao Liu, Zhonghua Yang, Jianping Peng
Biochemical and Biophysical Research Communications.2022; 622: 101. CrossRef
Tripartite Motif Containing 26 is a Positive Predictor for Endometrial Carcinoma Patients and Regulates Cell Survival in Endometrial Carcinoma
Tanmin Lu, Yu Wu
Hormone and Metabolic Research.2022; 54(12): 859. CrossRef
TRIM3 and TRIM16 as potential tumor suppressors in breast cancer patients
Mohammad Reza Roshanazadeh, Maryam Adelipour, Arash Sanaei, Hadi Chenane, Mojtaba Rashidi
BMC Research Notes.2022;[Epub] CrossRef
Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer
Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, Jeong-Hun Kang
Cancers.2022; 14(21): 5425. CrossRef
Transcriptional dysregulation of TRIM29 promotes colorectal cancer carcinogenesis via pyruvate kinase-mediated glucose metabolism
Jing Han, Zitong Zhao, Nan Zhang, Yang Yang, Liying Ma, Li Feng, Xue Zhang, Jing Zuo, Zhisong Fan, Yudong Wang, Yongmei Song, Guiying Wang
Aging.2021; 13(4): 5034. CrossRef
E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1
Xueqiang Deng, Xiaowei Fu, Hong Teng, Lu Fang, Bo Liang, Rengui Zeng, Lian Chen, Yeqing Zou
Journal of Translational Medicine.2021;[Epub] CrossRef
Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
Yang Wang, Huaicheng Tan, Ting Yu, Xiaoxuan Chen, Fangqi Jing, Huashan Shi
Frontiers in Immunology.2021;[Epub] CrossRef
TRIM29 in Cutaneous Squamous Cell Carcinoma
Che-Yuan Hsu, Teruki Yanagi, Hideyuki Ujiie
Frontiers in Medicine.2021;[Epub] CrossRef
Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways
Julie Girouard, Denise Belgorosky, Jovane Hamelin-Morrissette, Valerie Boulanger, Ernesto D'Orio, Djamel Ramla, Robert Perron, Lucie Charpentier, Céline Van Themsche, Ana Maria Eiján, Gervais Bérubé, Carlos Reyes-Moreno
Biochemical Pharmacology.2020; 176: 113778. CrossRef
Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation
Jia Sun, Jing Yan, Huai-Yu Qiao, Fu-Ying Zhao, Chao Li, Jing-Yi Jiang, Bao-Qin Liu, Xiao-Na Meng, Hua-Qin Wang
Oncogene.2020; 39(3): 546. CrossRef
The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members
Michael A. Mandell, Bhaskar Saha, Todd A. Thompson
Frontiers in Pharmacology.2020;[Epub] CrossRef
Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin

Zhibing Ou, Hua Zhong, Liang Zhang, Minghua Deng, Wenfeng Zhang, Jingyuan Wang, Huaguo Feng, Jianping Gong, Chunmu Miao, Zhujun Yi
International Journal of Nanomedicine.2020; Volume 15: 4125. CrossRef
TRIM59 inhibits PPM1A through ubiquitination and activates TGF-β/Smad signaling to promote the invasion of ectopic endometrial stromal cells in endometriosis
Fengyu Wang, Haili Wang, Lei Sun, Chengling Niu, Jie Xu
American Journal of Physiology-Cell Physiology.2020; 319(2): C392. CrossRef
TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin
Weifeng Xu, Beibei Chen, Dianshan Ke, Xiaobing Chen
Aging.2020; 12(13): 13488. CrossRef
Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p
Shunxiang Luo, Ming Shen, Hui Chen, Weiwei Li, Cong Chen
Molecular Medicine Reports.2020;[Epub] CrossRef
Robust Sample-Specific Stability Selection with Effective Error Control
Heewon Park, Makoto Yamada, Seiya Imoto, Satoru Miyano
Journal of Computational Biology.2019; 26(3): 202. CrossRef
Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway
Hao Shen, Jiawei Zhang, Yaodong Zhang, Qinchao Feng, Hongwei Wang, Gaochao Li, Wangjie Jiang, Xiangcheng Li
Gene.2019; 698: 50. CrossRef
MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29
Huimin Du, Qing Xu, Sheng Xiao, Zhenru Wu, Jianping Gong, Changan Liu, Guosheng Ren, Hao Wu
Life Sciences.2019; 224: 1. CrossRef
ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling
Yidong Cao, Luoning Shi, Maode Wang, Juanru Hou, Yanqiang Wei, Changwang Du
Chemico-Biological Interactions.2019; 305: 148. CrossRef
MicroRNA-621 inhibits cell proliferation and metastasis in bladder cancer by suppressing Wnt/β-catenin signaling
Haili Tian, Xiaoqiang Wang, Jianfeng Lu, Weiping Tian, Peijie Chen
Chemico-Biological Interactions.2019; 308: 244. CrossRef
Regulator of G protein signaling 20 promotes proliferation and migration in bladder cancer via NF-κB signaling
Gang Li, Meng Wang, Liangliang Ren, Hanzong Li, Qinghua Liu, Ying Ouyang, Lixin He, Fengyan Li
Biomedicine & Pharmacotherapy.2019; 117: 109112. CrossRef
ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK‐3β/Wnt/β‐catenin signalling
Weizhi Li, Hui Xue, Yingchao Li, Peijie Li, Fuquan Ma, Mengying Liu, Shuzhen Kong
Clinical and Experimental Pharmacology and Physiology.2019; 46(9): 845. CrossRef
MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression
Feng Li, Jing Liang, Lu Bai
Biomedicine & Pharmacotherapy.2018; 103: 782. CrossRef
iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma
Kun Wang, Zhen Chen, Lu Long, Ya Tao, Qiong Wu, Manlin Xiang, Yunlai Liang, Xulin Xie, Yuan Jiang, Zhiqiang Xiao, Yahui Yan, Shiyang Qiu, Bin Yi
Cancer Biology & Therapy.2018; 19(9): 809. CrossRef
TRIM29 as a prognostic predictor for multiple human malignant neoplasms: a systematic review and meta-analysis
Chao Liang, Huiyu Dong, Chenkui Miao, Jundong Zhu, Jie Wang, Pu Li, Jie Li, Zengjun Wang
Oncotarget.2018; 9(15): 12323. CrossRef
Overexpression of sigma‑1 receptor in MCF‑7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway
Yuqi Wu, Xueyan Bai, Xiaoyang Li, Chang Zhu, Zachary Wu
Oncology Letters.2018;[Epub] CrossRef
TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway
Ye Sun, Bing Ji, Yifei Feng, Yue Zhang, Dongjian Ji, Chunyan Zhu, Sen Wang, Chuan Zhang, Dongsheng Zhang, Yueming Sun
Oncology Reports.2017; 38(1): 43. CrossRef
TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway
Jinkai Xu, Zongyu Li, Qinghua Su, Jun Zhao, Jiancang Ma
Oncology Reports.2017; 37(3): 1555. CrossRef
Intravesicular administration of sodium hyaluronate ameliorates the inflammation and cell proliferation of cystitis cystica et glandularis involving interleukin-6/JAK2/Stat3 signaling pathway
Yongliang Ni, Shaohua Zhao, Xiaoxuan Yin, Haixin Wang, Qianqian Guang, Guangxia Hu, Yi Yang, Shoubin Jiao, Benkang Shi
Scientific Reports.2017;[Epub] CrossRef
High expression of TRIM29 (ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelial-mesenchymal transition in osteosarcoma
Si-Xiang Zeng, Qing-Chun Cai, Chi-Hua Guo, Li-Qiang Zhi, Xing Dai, Dang-Feng Zhang, Wei Ma
Oncology Reports.2017; 38(3): 1645. CrossRef
MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C
Xuefeng He, Jigen Ping, Duangai Wen
Experimental and Therapeutic Medicine.2017; 14(4): 3253. CrossRef

14,102 View
204 Download
49 Web of Science
46 Crossref

Decision Based on Narrow Band Imaging Cystoscopy without a Referential Normal Standard Rather Increases Unnecessary Biopsy in Detection of Recurrent Bladder Urothelial Carcinoma Early after Intravesical Instillation: Phil Hyun Song, Seok Cho, Young Hwii Ko; Cancer Res Treat. 2016;48(1):273-280. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.190

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to calculate the operating characteristics of narrowband imaging (NBI) cystoscopy versus traditional white light cystoscopy (WLC) in common clinical scenarios involving suspicion of bladder urothelial carcinoma (UC). Materials and Methods Sixty-three consecutive patients initially underwent WLC and then NBI in a single session for evaluation of microscopic hematuria (group I, n=20), gross hematuria (group II, n=19), and follow-up for prior UC (group III, n=24), by an experienced urologist. All lesions that were abnormal in contrast with adjacent normal mucosa were diagnosed as positive and biopsied.
Results
Sixty-six biopsies from 47 patients were performed. Pathologic examination showed 17 cases of UC from 21 sites. While the overall sensitivity of NBI was similar to that of WLC (100% vs. 94.1%), the specificity of NBI was significantly lower than that of WLC (50% vs. 86.9%, p < 0.001), particularly in group III (38.9% vs. 88.9%, p=0.004). Based on identification by NBI only, 23 additional biopsies from 18 cases were performed for identification of one patient with UC, who belonged to group III. In this group, to identify this specific patient, 15 additional biopsies were performed from 10 patients. All seven cases with positive findings from NBI within 2 months after the last intravesical therapy were histologically proven as negative. Conclusion In evaluation for recurrence early after intravesical instillation, the decision based on NBI increased unnecessary biopsy in the absence of an established standard for judging NBI.

Citations

Citations to this article as recorded by

Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer
Raghavendra RT, Amit Sharma, Deepak Biswal, Saryu Goel
Urologia Journal.2024; 91(2): 289. CrossRef
Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review
Marinka J. Remmelink, Yael Rip, Jakko A. Nieuwenhuijzen, Johannes C.F. Ket, Jorg R. Oddens, Theo M. de Reijke, Daniel M. de Bruin
BJU International.2024; 134(6): 890. CrossRef
Differentiation of Urothelial Carcinoma and Normal Bladder Tissues by Means of Fiber-Based ATR IR Spectroscopy
Rimantė Bandzevičiūtė, Gediminas Platkevičius, Justinas Čeponkus, Arūnas Želvys, Albertas Čekauskas, Valdas Šablinskas
Cancers.2023; 15(2): 499. CrossRef
Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging
Hao Liang, Qingya Yang, Yaozhong Zhang, Hui Sun, Qiang Fu, Tongxiang Diao, Jin Wang, Wei Huang, Yang Xu, Nan Ge, Xuewen Jiang, Shouzhen Chen, Yan Li, Bin Zhou, Peixin Li, Xiaoyi Zhang, Nianzhao Zhang, Benkang Shi, Jun Chen
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15867. CrossRef
Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review
Prashant Motiram Mulawkar, Gyanendra Sharma, Ashwin Tamhankar, Utsav Shah, Rickaz Raheem
Frontiers in Surgery.2022;[Epub] CrossRef
Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis
Giorgio I. Russo, Tamir N. Sholklapper, Andrea Cocci, Giuseppe Broggi, Rosario Caltabiano, Angela B. Smith, Yair Lotan, Giuseppe Morgia, Ashish M. Kamat, J. Alfred Witjes, Siamak Daneshmand, Mihir M. Desai, Indebir S. Gill, Giovanni E. Cacciamani
Cancers.2021; 13(17): 4378. CrossRef
Postoperative Recurrent Bladder Tumors Detection by Narrow-Band Imaging Cystoscopy
Won Tae Seo, Su Hwan Kang
The Korean Journal of Urological Oncology.2020; 18(3): 209. CrossRef
Blue-light cystoscopy and narrow-band imaging in bladder cancer management
Zhijiang Zang, Qinghui Wu, Edmund Chiong
Formosan Journal of Surgery.2019; 52(5): 155. CrossRef
Usefulness of narrow-band imaging in transurethral resection of bladder tumor: Early experience from a tertiary center in India
Kanuj Malik, Anand Raja, Sivakumar Mahalingam, L.S Ravishankar
South Asian Journal of Cancer.2019; 08(04): 226. CrossRef
Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis
Changhao Chen, Hao Huang, Yue Zhao, Hao Liu, Richard Sylvester, Tianxin Lin, Jian Huang
BMJ Open.2019; 9(10): e028173. CrossRef
Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy
Seung Bin Kim, Sung Goo Yoon, Jonghyun Tae, Jae Yoon Kim, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Je Jong Kim, Seok Ho Kang
Investigative and Clinical Urology.2018; 59(2): 98. CrossRef
A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer
YiQuan Xiong, JianDong Li, ShuJuan Ma, Jing Ge, LiZhi Zhou, Dongliang Li, Qing Chen, Robert Hurst
PLOS ONE.2017; 12(2): e0170819. CrossRef
Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis
Weiting Kang, Zilian Cui, Qianqian Chen, Dong Zhang, Haiyang Zhang, Xunbo Jin
Oncotarget.2017; 8(14): 23880. CrossRef
Narrow band imaging for bladder cancer
Thomas Y. Hsueh, Allen W. Chiu
Asian Journal of Urology.2016; 3(3): 126. CrossRef

15,335 View
92 Download
14 Web of Science
14 Crossref

Detecting Metastatic Bladder Cancer Using ¹⁸F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography: Hakan Öztürk; Cancer Res Treat. 2015;47(4):834-843. Published online February 12, 2015; DOI: https://doi.org/10.4143/crt.2014.157

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose- positron emission tomography/computed tomography (18F-FDG-PET/CT) to detection of metastatic bladder cancer. Materials and Methods The present study included 79 patients (69 men and 10 women) undergoing 18F-FDGPET/ CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85 years). Patients were required to fast for 6 hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 hour after intravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. Results The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. Conclusion 18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive values in patients with metastatic bladder carcinoma.

Citations

Citations to this article as recorded by

Maximizing Outcomes with Chemoimmunotherapy in Lymph Node–only Metastatic Urothelial Cancer: Targeting a Favorable Subgroup
Charles B. Nguyen, Wesley Yip
European Urology.2025; 88(4): 339. CrossRef
Radiotherapy in metastatic bladder cancer
Sophie Ashley, Ananya Choudhury, Peter Hoskin, YeePei Song, Priyamvada Maitre
World Journal of Urology.2024;[Epub] CrossRef
PET Imaging in Bladder Cancer: An Update and Future Direction
Jules Zhang-Yin, Antoine Girard, Etienne Marchal, Thierry Lebret, Marie Homo Seban, Marine Uhl, Marc Bertaux
Pharmaceuticals.2023; 16(4): 606. CrossRef
Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy
Olivier Fitoussi, Jean Baptiste Roche, Julien Riviere, Hervé Wallerand, Jean Eude Poulain, Pierre Gordien, Sigolène Galland, Bénédicte Henriques, Camille Dupin, Muriel Vincent, Thomas Kuratle, Mo Saffarini, Sonia Ramos-Pascual
Urologia Internationalis.2023; 107(3): 239. CrossRef
PET/CT in Bladder Cancer: An Update
Kirsten Bouchelouche
Seminars in Nuclear Medicine.2022; 52(4): 475. CrossRef
Quantitative positron emission tomography imaging in the presence of iodinated contrast media using electron density quantifications from dual‐energy computed tomography
Nadav Shapira, Joshua Scheuermann, Amy E. Perkins, Johoon Kim, Leening P Liu, Joel S. Karp, Peter B. Noël
Medical Physics.2021; 48(1): 273. CrossRef
18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer
Sarah M.H. Einerhand, Erik J. van Gennep, Laura S. Mertens, Kees Hendricksen, Maarten L. Donswijk, Henk G. van der Poel, Bas W.G. van Rhijn
Current Opinion in Urology.2020; 30(5): 654. CrossRef
The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma
Antoine Girard, Helena Vila Reyes, Hiram Shaish, Jean-François Grellier, Laurent Dercle, Pierre-Yves Salaün, Olivier Delcroix, Mathieu Rouanne
Frontiers in Oncology.2020;[Epub] CrossRef
Cancers de la vessie
A. Girard, J.F. Grellier, P.Y. Salaün
Médecine Nucléaire.2019; 43(1): 69. CrossRef
Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
Antoine Girard, Mathieu Rouanne
European Journal of Nuclear Medicine and Molecular Imaging.2019; 46(6): 1212. CrossRef
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
Fabio Zattoni, Elena Incerti, Michele Colicchia, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Marco Moschini, Andrea Gallina, Jeffrey R. Karnes, Val Lowe, Stefano Fanti, Riccardo Schiavina, Ilaria Rambaldi, Vince
Abdominal Radiology.2018; 43(9): 2391. CrossRef
The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis
Anna Rita Cervino, Lea Cuppari, Pasquale Reccia, Marta Burei, Giorgio Saladini, Laura Evangelista
Clinical and Translational Imaging.2018; 6(2): 77. CrossRef
Pelvic Lymph Node Staging by Combined 18F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy
Renate Pichler, Tobias De Zordo, Josef Fritz, Alexander Kroiss, Friedrich Aigner, Isabel Heidegger, Irene Virgolini, Wolfgang Horninger, Christian Uprimny
Clinical Genitourinary Cancer.2017; 15(3): e387. CrossRef
Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness
Julieta Afonso, Lúcio L. Santos, António Morais, Teresina Amaro, Adhemar Longatto-Filho, Fátima Baltazar
Cell Cycle.2016; 15(3): 368. CrossRef
The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy
William P. Parker, Philip L. Ho, Stephen A. Boorjian, Jonathan J. Melquist, Prabin Thapa, Jeffrey M. Holzbeierlein, Igor Frank, Ashish M. Kamat, Eugene K. Lee
World Journal of Urology.2016; 34(11): 1561. CrossRef

17,319 View
105 Download
20 Web of Science
15 Crossref

APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer: Ju Hyun Shin, Sunga Choi, Yu Ran Lee, Myoung Soo Park, Yong Gil Na, Kaikobad Irani, Sang Do Lee, Jin Bong Park, Jin Man Kim, Jae Sung Lim, Byeong Hwa Jeon; Cancer Res Treat. 2015;47(4):823-833. Published online January 2, 2015; DOI: https://doi.org/10.4143/crt.2014.074

Abstract PDF PubReader ePub

Purpose
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer.
Materials and Methods
Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1.
Results
Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548±0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547±0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence.
Conclusion
Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.

Citations

Citations to this article as recorded by

A dual-switch fluorescence biosensor with an entropy-driven and DNA walker cascade amplification circuit for sensitive microRNA detection
Zikang Xie, Zhaolong Tang, Xindie Zhuang, Xinhao Li, Baozheng Wang, Hong Wang, Yingwei Zhang
Nanoscale.2025; 17(13): 8153. CrossRef
Targeting APE1: Advancements in the Diagnosis and Treatment of Tumors
Minghui Hu, Yingyu Zhang, Pin Zhang, Kangbo Liu, Mengxin Zhang, Lifeng Li, Zhidan Yu, Xianwei Zhang, Wancun Zhang, Ying Xu
Protein & Peptide Letters.2025; 32(1): 18. CrossRef
PAM triggered visual “green-yellow-orange” ratiometric fluorescence probes in CRISPR/Cas12a: Universal detection of exosome and APE1
Zhigang Liang, Xiang Chen, Yan Yu, Guanhong Xu, Fangdi Wei, Jing Yang, Qin Hu, Yao Cen
Microchemical Journal.2025; 214: 114010. CrossRef
Enzyme-Activated Biosensor Assisted by Enzymatic Rolling Circle Amplification for Sensitive Detection of APE1 and Imaging in Vivo
Chuan Zhao, Siyuan Liu, Wenya Dang, Qing Liu, Danni Yin, Bin Liu, Chunsheng Hou
Analytical Chemistry.2025; 97(30): 16690. CrossRef
APE1/Ref‐1 inhibition via APX3330 lowers monocyte/macrophage infiltration without ameliorating the structure and function of dystrophic mdx hindlimb muscles
Hannah Lalunio, Craig A. Goodman, Nicole Stupka, Nicholas Giourmas, Danielle A. Debruin, Lauren Sahakian, Kulmira Nurgali, Alan Hayes
Physiological Reports.2025;[Epub] CrossRef
Detection and in situ imaging of APE1 through self-initiated hyperbranched hybridization chain reaction of multifunctional DNA tetrahedral nanoprobes
Sha Lu, Qiong Wang, Zhi-Qi Dai, Chen-Yu Wang, Jing Wang, Zhi-Li Yao, Jin-Ming Liu, Quan Chen, Qi-Liang Cai, Yun-Xi Cui, De-Ming Kong
Sensors and Actuators B: Chemical.2025; 443: 138171. CrossRef
Sensitive detection of miRNA-141 using an endogenous dual-switch activated bipedal DNAzyme walker biosensor
Beibei Zhang, Xinyi Wang, Min Pan, Xinhao Li, Hong Wang, Yingwei Zhang
Nanoscale.2025; 17(35): 20199. CrossRef
Leveraging CRISPR/Cas12 signal amplifier to sensitive detection of apurinic/apyrimidinic endonuclease 1 and high-throughput inhibitor screening
Sheng Ding, Yi Yuan, Juan Dong, Feng Du, Xin Cui, Zheng Shi, Zhuo Tang
Analytica Chimica Acta.2024; 1291: 342212. CrossRef
Protective Effect of Secretory APE1/Ref-1 on Doxorubicin-Induced Cardiotoxicity via Suppression of ROS and p53 Pathway
Soo Yeon An, Seon-Ah Jin, Hee Jeong Seo, Yu Ran Lee, Sungmin Kim, Byeong Hwa Jeon, Jin-Ok Jeong
ESC Heart Failure.2024; 11(2): 1182. CrossRef
Enhancing APE1 detection through apurinic/apyrimidinic site inhibition of DNA polymerase: an innovative, highly sensitive approach
Zhijun Liu, Bei Yan, Huan Liu, Xiao Liu, Xianjin Xiao, Zhihao Ming
Chemical Communications.2024; 60(35): 4695. CrossRef
The DNA-repair protein APE1 participates with hnRNPA2B1 to motif-enriched and prognostic miRNA secretion
Giovanna Mangiapane, Michela Notarangelo, Giulia Canarutto, Fabrizio Fabbiano, Emiliano Dalla, Monica Degrassi, Giulia Antoniali, Nicolò Gualandi, Veronica De Sanctis, Silvano Piazza, Vito Giuseppe D’Agostino, Gianluca Tell
Oncogene.2024; 43(24): 1861. CrossRef
Dual-driven AND molecular logic gates for label-free and sensitive ratiometric fluorescence sensing and inhibitors screening
Qiongdan Zhang, Qingyi Liu, Gang Fu, Feibing Huang, Yanfu Tang, Yixing Qiu, Anqi Ge, Jinhui Hu, Wei Wang, Bin Li, Huizhen Wang
Journal of Colloid and Interface Science.2024; 674: 841. CrossRef
A recognition-induced three-dimensional bipedal DNA walker for highly sensitive detection of APE1
Qingyi Liu, Qiongdan Zhang, Yuting Zhang, Fanghong Tian, Kang Long, Yupei Yang, Wei Wang, Caiyun Peng, Huizhen Wang
Analytical Methods.2024; 16(36): 6220. CrossRef
Role of APE1 in hepatocellular carcinoma and its prospects as a target in clinical settings (Review)
Lei Yang, Zhipeng Sun
Molecular and Clinical Oncology.2024;[Epub] CrossRef
A multifunctional DNA repair enzyme and magnetic dual-triggered theranostic nanosystem for intelligent drug delivery
Zhuo Peng, Keni Ning, Xiaoyan Tang, Ruikai He, Dong-Yang Zhang, Yan Ma, Shixia Guan, Junqiu Zhai
Materials & Design.2023; 226: 111611. CrossRef
Electrochemical biosensor based on bipedal DNA walker for highly sensitive amplification detection of apurinic/apyrimidinic endonuclease 1
Xingcong Wang, Jinting Meng, Haoping Zhang, Jingyan Mou, Jinping Xiong, Hong Wang, Xin Su, Yingwei Zhang
Sensors and Actuators B: Chemical.2023; 381: 133425. CrossRef
An AND‐Gate DNA Nanodevice for Dual Protein‐Mediated, Tumor‐Specific Imaging
Zetan Fan, Fangzhi Yu, Mingming Yu, Lele Li
Chinese Journal of Chemistry.2023; 41(12): 1437. CrossRef
Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons
Matilde Clarissa Malfatti, Alessia Bellina, Giulia Antoniali, Gianluca Tell
Cells.2023; 12(14): 1895. CrossRef
Elevated Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 Levels in Refractory Kawasaki Disease
Yu-Ran Lee, Eun Young Bae, Hong Ryang Kil, Byeong-Hwa Jeon, Geena Kim
Biomedicines.2022; 10(1): 190. CrossRef
Mechanistic decoupling of exonuclease III multifunctionality into AP endonuclease and exonuclease activities at the single-residue level
Donghun Lee, Sanghoon Oh, HyeokJin Cho, Jungmin Yoo, Gwangrog Lee
Nucleic Acids Research.2022; 50(4): 2211. CrossRef
APE1/Ref-1 Role in Inflammation and Immune Response
Thais Teixeira Oliveira, Leonam Gomes Coutinho, Laysa Ohana Alves de Oliveira, Ana Rafaela de Souza Timoteo, Guilherme Cavalcanti Farias, Lucymara Fassarella Agnez-Lima
Frontiers in Immunology.2022;[Epub] CrossRef
“RESET” Effect: Random Extending Sequences Enhance the Trans-Cleavage Activity of CRISPR/Cas12a
Jia-Yi Ma, Si-Yuan Wang, Yi-Chen Du, Dong-Xia Wang, An-Na Tang, Jing Wang, De-Ming Kong
Analytical Chemistry.2022; 94(22): 8050. CrossRef
A dual-functional fluorescent biosensor based on enzyme-involved catalytic hairpin assembly for the detection of APE1 and miRNA-21
Xiaoyong Lu, Dan Li, Zewei Luo, Yixiang Duan
The Analyst.2022; 147(12): 2834. CrossRef
Incorporating quaternary mesoporous nanospheres and DNA stochastic nanowalkers into a signal amplified switch: A highly sensitive electrochemical assay for APE1
Qingsong Wei, Zhisheng Teng, Xuelian Luo, Yuxin Yang, Yuxia Ren, Wenbin Liang, Ying Zhuo, Zhaoyang Zhong
Sensors and Actuators B: Chemical.2022; 370: 132386. CrossRef
Identification and Quantification of Apurinic/Apyrimidinic Endonuclease 1 in Human Peripheral Blood Leukocytes by Liquid Chromatography/Isotope-Dilution High Resolution Mass Spectrometry
Gamze TUNA
Journal of Basic and Clinical Health Sciences.2022; 6(3): 851. CrossRef
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease
Rachel A. Caston, Silpa Gampala, Lee Armstrong, Richard A. Messmann, Melissa L. Fishel, Mark R. Kelley
Drug Discovery Today.2021; 26(1): 218. CrossRef
A DNA structure-mediated fluorescent biosensor for apurinic/apyrimidinic endonuclease 1 activity detection with ultra-high sensitivity and selectivity
Yuqiang Hu, Zhen Zhang, Weicong Ye, Wei Zhang, Minghao Hu, Wenqian Yuan, Hongbo Wang, Xianjin Xiao, Tongbo Wu
Sensors and Actuators B: Chemical.2021; 330: 129332. CrossRef
Spectroscopic sensing and quantification of AP-endonucleases using fluorescence-enhancement by cis–trans isomerization of cyanine dyes
JunHo Cho, Sanghoon Oh, DongHun Lee, Jae Won Han, Jungmin Yoo, Daeho Park, Gwangrog Lee
RSC Advances.2021; 11(19): 11380. CrossRef
Enzymatically active apurinic/apyrimidinic endodeoxyribonuclease 1 is released by mammalian cells through exosomes
Giovanna Mangiapane, Isabella Parolini, Kristel Conte, Matilde Clarissa Malfatti, Jessica Corsi, Massimo Sanchez, Agostina Pietrantoni, Vito G. D’Agostino, Gianluca Tell
Journal of Biological Chemistry.2021; 296: 100569. CrossRef
APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival
Heyu Song, Jiping Zeng, Subodh Lele, Chad A. LaGrange, Kishor K. Bhakat
Heliyon.2021; 7(4): e06756. CrossRef
Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer
Asmat Ullah, Sze Wei Leong, Jingjing Wang, Qing Wu, Mohsin Ahmad Ghauri, Ammar Sarwar, Qi Su, Yanmin Zhang
Cell Death & Disease.2021;[Epub] CrossRef
A Cooperatively Activatable, DNA‐based Fluorescent Reporter for Imaging of Correlated Enzymatic Activities
Zetan Fan, Jian Zhao, Xin Chai, Lele Li
Angewandte Chemie.2021; 133(27): 15013. CrossRef
A Cooperatively Activatable, DNA‐based Fluorescent Reporter for Imaging of Correlated Enzymatic Activities
Zetan Fan, Jian Zhao, Xin Chai, Lele Li
Angewandte Chemie International Edition.2021; 60(27): 14887. CrossRef
Blood-based protein biomarkers in bladder urothelial tumors
Rubén López-Cortés, Benito Blanco Gómez, Sergio Vázquez-Estévez, Daniel Pérez-Fentes, Cristina Núñez
Journal of Proteomics.2021; 247: 104329. CrossRef
Changes in the Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1(APE1/Ref-1) Level during Cancer Surgery: An Observational Study
Yumin Jo, Yeojung Kim, Eunhye Park, Yuran Lee, Jiyeon Kim, Minwoong Kang, Jaesung Lim, Insang Song, Chaeseong Lim, Byeonghwa Jeon
Medicina.2021; 57(11): 1280. CrossRef
Nucleases as molecular targets for cancer diagnosis
Alien Balian, Frank J. Hernandez
Biomarker Research.2021;[Epub] CrossRef
Graphene Quantum Dot-Based Nanocomposites for Diagnosing Cancer Biomarker APE1 in Living Cells
Hao Zhang, Sai Ba, Zhaoqi Yang, Tianxiang Wang, Jasmine Yiqin Lee, Tianhu Li, Fangwei Shao
ACS Applied Materials & Interfaces.2020; 12(12): 13634. CrossRef
The Biological Role of Apurinic/Apyrimidinic Endonuclease1/Redox Factor-1 as a Therapeutic Target for Vascular Inflammation and as a Serologic Biomarker
Yu Ran Lee, Hee Kyoung Joo, Byeong Hwa Jeon
Biomedicines.2020; 8(3): 57. CrossRef
Non-muscle invasive bladder cancer tissues have increased base excision repair capacity
Berna Somuncu, Selcuk Keskin, Fatma Merve Antmen, Yesim Saglican, Aysegul Ekmekcioglu, Tugce Ertuzun, Mustafa Bilal Tuna, Can Obek, David M. Wilson, Umit Ince, Ali Riza Kural, Meltem Muftuoglu
Scientific Reports.2020;[Epub] CrossRef
Correlation of APE1 with VEGFA and CD163+ macrophage infiltration in bladder cancer and their prognostic significance
Lin-Ang Wang, Bo Yang, Tang Tang, Yuxin Yang, Dianzheng Zhang, Hualiang Xiao, Jing Xu, Luofu Wang, Li Lin, Jun Jiang
Oncology Letters.2020; 20(3): 2881. CrossRef
Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Could Serve as a Potential Serological Biomarker for the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma
Jianli Xie, Ying Li, Jingjing Kong, Chong Li
Journal of Oral and Maxillofacial Surgery.2019; 77(4): 859. CrossRef
The extracellular role of Ref-1 as anti-inflammatory function in lipopolysaccharide-induced septic mice
Hee Kyoung Joo, Yu Ran Lee, Eun-Ok Lee, Myoung Soo Park, Sunga Choi, Cuk-Seong Kim, Jin-Bong Park, Byeong Hwa Jeon
Free Radical Biology and Medicine.2019; 139: 16. CrossRef
ATP Binding Cassette Transporter A1 is Involved in Extracellular Secretion of Acetylated APE1/Ref-1
Yu Ran Lee, Hee Kyoung Joo, Eun Ok Lee, Hyun Sil Cho, Sunga Choi, Cuk-Seong Kim, Byeong Hwa Jeon
International Journal of Molecular Sciences.2019; 20(13): 3178. CrossRef
An electrochemical biosensor integrating immunoassay and enzyme activity analysis for accurate detection of active human apurinic/apyrimidinic endonuclease 1
Mengru Zhou, Chang Feng, Dongsheng Mao, Shiqi Yang, Lingjie Ren, Guifang Chen, Xiaoli Zhu
Biosensors and Bioelectronics.2019; 142: 111558. CrossRef
APEX1 Expression as a Potential Diagnostic Biomarker of Clear Cell Renal Cell Carcinoma and Hepatobiliary Carcinomas
Ji-Myung Kim, Min-Kyung Yeo, Jae Lim, In-Sang Song, Kwangsik Chun, Kyung-Hee Kim
Journal of Clinical Medicine.2019; 8(8): 1151. CrossRef
Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma
Doungdean Tummanatsakun, Tanakorn Proungvitaya, Sittiruk Roytrakul, Temduang Limpaiboon, Sopit Wongkham, Chaisiri Wongkham, Atit Silsirivanit, Ongart Somintara, Sakkarn Sangkhamanon, Siriporn Proungvitaya
Biomolecules.2019; 9(9): 413. CrossRef
Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma
Devis Pascut, Caecilia Hapsari Ceriapuri Sukowati, Giulia Antoniali, Giovanna Mangiapane, Silvia Burra, Luca Giovanni Mascaretti, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, Gianluca Tell
Oncotarget.2019; 10(3): 383. CrossRef
Apurinic/apyrimidinic endonuclease/redox factor 1 (APE1) alleviates myocardial hypoxia‑reoxygenation injury by inhibiting oxidative stress and ameliorating mitochondrial dysfunction
Jie Hao, Hong Du, Fan Liu, Jing‑Chao Lu, Xiu‑Chun Yang, Wei Cui
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Melissa L. Fishel, Hanyu Xia, Jack McGeown, David W. McIlwain, May Elbanna, Ariel A. Craft, Hristos Z. Kaimakliotis, George E. Sandusky, Chi Zhang, Roberto Pili, Mark R. Kelley, Travis J. Jerde
Molecular Cancer Therapeutics.2019; 18(11): 1947. CrossRef
Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo
Yu Ran Lee, Myoung Soo Park, Hee Kyoung Joo, Ki Mo Kim, Jeryong Kim, Byeong Hwa Jeon, Sunga Choi
Scientific Reports.2018;[Epub] CrossRef
Differential expression of APE1 in hepatocellular carcinoma and the effects on proliferation and apoptosis of cancer cells
Zhipeng Sun, Yubing Zhu, Aminbuhe, Qing Fan, Jirun Peng, Nengwei Zhang
BioScience Trends.2018; 12(5): 456. CrossRef
DNA base excision repair proteins APE‐1 and XRCC‐1 are overexpressed in oral tongue squamous cell carcinoma
Thalita Santana, Melka Coêlho Sá, Edilmar de Moura Santos, Hébel Cavalcanti Galvão, Ricardo D. Coletta, Roseana de Almeida Freitas
Journal of Oral Pathology & Medicine.2017; 46(7): 496. CrossRef
A graphene oxide-based tool-kit capable of characterizing and classifying exonuclease activities
Jayeon Song, Vo Minh Hoa, Jungmin Yoo, Sanghoon Oh, Hyeryeon Im, Daeho Park, Gwangrog Lee
RSC Advances.2017; 7(24): 14917. CrossRef
Apurinic/apyrimidinic endonuclease 1 (APE1) is overexpressed in malignant transformation of salivary gland pleomorphic adenoma
Leorik Pereira Silva, Thalita Santana, Bruno Tavares Sedassari, Suzana Machado de Sousa, Ana Paula Veras Sobral, Roseana de Almeida Freitas, Carlos Augusto Galvão Barboza, Lélia Batista de Souza
European Archives of Oto-Rhino-Laryngology.2017; 274(8): 3203. CrossRef
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
npj Precision Oncology.2017;[Epub] CrossRef
APE1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cellRNAsequencing
Fenil Shah, Emery Goossens, Nadia M. Atallah, Michelle Grimard, Mark R. Kelley, Melissa L. Fishel
Molecular Oncology.2017; 11(12): 1711. CrossRef
Elevation of Serum APE1/Ref-1 in Experimental Murine Myocarditis
Seon-Ah Jin, Byung-Kwan Lim, Hee Seo, Sun Kim, Kye Ahn, Byeong Jeon, Jin-Ok Jeong
International Journal of Molecular Sciences.2017; 18(12): 2664. CrossRef
APE1 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis
Chun-Ling Yuan, Fan He, Jia-Zhou Ye, Hui-Ni Wu, Jin-Yan Zhang, Zhi-Hui Liu, Yong-Qiang Li, Xiao-Ling Luo, Yan Lin, Rong Liang
Oncotarget.2017; 8(35): 59720. CrossRef
Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
Sunga Choi, Ju Hyun Shin, Yu Ran Lee, Hee Kyoung Joo, Ki Hak Song, Yong Gil Na, Seok Jong Chang, Jae Sung Lim, Byeong Hwa Jeon
Disease Markers.2016; 2016: 1. CrossRef
Secreted APE1/Ref-1 inhibits TNF-α-stimulated endothelial inflammation via thiol-disulfide exchange in TNF receptor
Myoung Soo Park, Sunga Choi, Yu Ran Lee, Hee Kyoung Joo, Gun Kang, Cuk-Seong Kim, Soo Jin Kim, Sang Do Lee, Byeong Hwa Jeon
Scientific Reports.2016;[Epub] CrossRef
Altered Secretory Activity of APE1/Ref-1 D148E Variants Identified in Human Patients With Bladder Cancer
Yu Ran Lee, Jae Sung Lim, Ju Hyun Shin, Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
International Neurourology Journal.2016; 20(Suppl 1): S30. CrossRef
Dynamic Regulation of APE1/Ref-1 as a Therapeutic Target Protein
Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
Chonnam Medical Journal.2016; 52(2): 75. CrossRef
Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
Shiheng Zhang, Le He, Nan Dai, Wei Guan, Jinlu Shan, Xueqin Yang, Zhaoyang Zhong, Yi Qing, Feng Jin, Chuan Chen, Yuxin Yang, Hongyi Wang, Laura Baugh, Gianluca Tell, David M. Wilson, Mengxia Li, Dong Wang
Oncotarget.2016; 7(47): 77482. CrossRef

17,228 View
141 Download
64 Web of Science
63 Crossref

Case Report

A Case of Synchronous Double Primary Cancer of the Penis and Urinary Bladder: Yong Soo Cho, Jung-Ae Lee, Si Bum Kim, Soo Jung Gong, Joo Heon Kim, Seon Min Youn, Eun Tak Kim; Cancer Res Treat. 2010;42(1):53-56. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.53

Abstract PDF PubReader ePub

Multiple primary cancers are the occurrence of more than two cancers of different origin in an individual. Penile cancer is a rare disease, and finding it combined with other cancers is even rarer. A 64-year-old man with a painful penile mass was referred to us from a primary urological clinic. We performed a biopsy of the penile mass and the histology revealed a well-differentiated squamous cell carcinoma. Abdominal computed tomography showed a localized bladder tumor with inguinal lymphadenopathy. The patient underwent a partial penectomy, transurethral resection of the bladder tumor and inguinal lymph node dissection. The histology of the bladder tumor was high-grade papillary carcinoma, and that of the lymph node was squamous cell carcinoma. The penile and bladder tumors were in stage II (T1N1M0) and stage I (T1N0M0), respectively. We successfully treated the patient with adjuvant radiotherapy and systemic chemotherapy.

Citations

Citations to this article as recorded by

A rare case report of synchronous renal cell carcinoma and penile carcinoma
Indra Prakash Mandal, Krishnendu Maiti, Debansu Sarkar
Annals of Medical Science & Research.2025; 4(2): 108. CrossRef
Synchronous Double Primary Cancer of the Penisand Urinary Bladder
Deora H
MOJ Surgery.2017;[Epub] CrossRef

10,195 View
93 Download
2 Crossref

First
Prev
Page of 1
Next
Last

Search